Botanix Pharmaceuticals Ltd has released a press release.
Presentation on Atopic Dermatitis Market
Filed with ASX ·
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Botanix Pharmaceuticals Limited on 6ix
In the deck
Earlier from Botanix Pharmaceuticals
- FDA Green Light for BTX 1503 Phase 2 Study
- Appendix 4C - quarterly
- Enrolment of BTX 1204 Atopic Dermatitis Study Completed
- Completion of Placement
- Significantly Oversubscribed A$15m Placement
Later from Botanix Pharmaceuticals
- Botanix Announces Successful Atopic Dermatitis Study Results
- BTX 1204 Atopic Dermatitis Study Results Presentation
- Australian Ethics approval for Acne Study
- Botanix Raises A$8m in Oversubscribed Placement
- BOT Welcomes First FDA Approval for Cannabidiol Product
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals